Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (131)Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial
Preheader (150)Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable li
Typography
Arial
Colors
Text Analysis
Body Words158
Subject Words21
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px814 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial

Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable li
Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial